Evidence map›Paper›PMID 40636477›Full record

ArticleiLIVER2024

CCL16 inhibits tumor proliferation and metastasis in HCC by impacting CK19 phenotype.

Huigang Li, Jianyong Zhuo, Peiru Zhang, Jinyan Chen, Zuyuan Lin, Xudong Yang, Ruijie Zhao, Chenghao Cao, Wei Shen, Chiyu He and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iLIVER, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Huigang LiZhejiang University School of Medicine, Hangzhou 310058, China.
Jianyong ZhuoDepartment of Hepatobiliary and Pancreatic Surgery, Hangzhou First People's Hospital, Hangzhou 310006, China.
Peiru ZhangThe Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou 310000, China.
Jinyan ChenZhejiang University School of Medicine, Hangzhou 310058, China.
Zuyuan LinZhejiang University School of Medicine, Hangzhou 310058, China.
Xudong YangHangzhou Normal University, Hangzhou 310000, China.
Ruijie ZhaoZhejiang University School of Medicine, Hangzhou 310058, China.
Chenghao CaoZhejiang University School of Medicine, Hangzhou 310058, China.
Wei ShenZhejiang University School of Medicine, Hangzhou 310058, China.
Chiyu HeZhejiang University School of Medicine, Hangzhou 310058, China.
Hao ChenZhejiang University School of Medicine, Hangzhou 310058, China.
Ting LvKey Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Hangzhou 310000, China.
Xuyong WeiDepartment of Hepatobiliary & Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou 310014, China.
Shusen ZhengNHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou 310003, China.
Xiao XuDepartment of Hepatobiliary & Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou 310014, China.
Di LuDepartment of Hepatobiliary & Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou 310014, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aims: Cytokeratin 19-positive (CK19+) hepatocellular carcinoma (HCC) is an aggressive subtype with poor outcomes. The initiation and development of CK19+ HCC in the background of liver cirrhosis remains unclear. This study investigated the role of the cirrhosis-related gene C-C motif chemokine ligand 16 (CCL16) in the development of CK19+ HCC. Methods: Datasets from Gene Expression Omnibus (GEO), The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) were analyzed to screen and validate the genes associated with CK19+ HCC. A total of 102 HCC patients were included for tissue microarray analysis. Gain-of-function experiments were conducted to investigate the biological functions of CCL16. CIBERSORT was used to investigate the correlation of CCL16 and immune infiltration. Results: GEO dataset analysis showed that CK19+ HCC had lower expression of CCL16. In both TCGA dataset and our HCC cohort, CCL16 expression was negatively correlated with CK19 expression ( Conclusion: Our data indicated that CCL16 downregulated the expression of CK19 and inhibited the malignant phenotype of HCC.

Indexed as

C–C motif chemokine ligand 16Cytokeratin 19Hepatocellular carcinomaMast cellsPrognosis

Identifiers

PMID40636477
PMCPMC12212685

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.